<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865876</url>
  </required_header>
  <id_info>
    <org_study_id>CEI-2015/01/02</org_study_id>
    <nct_id>NCT02865876</nct_id>
  </id_info>
  <brief_title>Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis</brief_title>
  <official_title>Effectiveness of Corneal Accelerated Crosslinking Versus Conventional Treatment for Infectious Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Oftalmología Fundación Conde de Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Oftalmología Fundación Conde de Valenciana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of accelerated
      cross-linking (Avedro Inc., Waltham, USA) in the management of microbial keratitis as
      adjunctive therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators perform a comprehensive ophthalmological examination, including evaluation of
      risk factors (immunosuppressive status, ocular trauma, previous ocular surgery, contact lens
      wear, topical corticosteroids use), best-corrected visual acuity (Snellen chart), slit-lamp
      biomicroscopy, tonometry and fundoscopy. In addition, anterior segment optical coherence
      tomography imaging (Visante, Carl Zeiss Meditec, Dublin, California, USA), corneal scrapes,
      culture and clinical photographs at day 1, day 7, month 1 and 3 will be analyzed.

      Each participant will be assigned to one of four groups after randomization. Group 1: Initial
      ulcer on treatment with antibiotic plus sham (n = 66), these partcipants will receive only
      topical moxifloxacin 0,5% (Vigamoxi, Alcon, Texas, USA) and sham CXL; Group 2: Initial ulcer
      on treatment with antibiotic plus cross-linking (CXL) (n = 66) receive moxifloxacin plus CXL
      (riboflavin 0.1% during 10 minutes and irradiation 30 mW/cm2 during 3 minutes using
      accelerated CXL); Group 3: Refractory corneal ulcer on treatment with antibiotic plus sham
      (n=66), receive only topical antibiotic plus sham CXL; Group 4: Refractory corneal ulcer on
      treatment with antibiotic plus CXL will receive their standard medications plus CXL.

      Statistical analysis will be divided into four phases: 1) Analysis of compliance, 2)
      Intention to treat, 3) Losses to follow-up and 4) Variable-response (healing) using Stata/MP
      12.0 (Stata Corp., College Station, TX).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing</measure>
    <time_frame>Three months</time_frame>
    <description>Full epithelialization without evidence of infiltrates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Three months</time_frame>
    <description>Complications associated with accelerated corneal cross-linking, such as corneal perforation or progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Keratitis</condition>
  <arm_group>
    <arm_group_label>Accelerated Corneal Cross-linking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Accelerated Corneal Cross-linking</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted &quot;the impregnation phase&quot; applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Accelerated Corneal Cross-linking</intervention_name>
    <description>All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.</description>
    <arm_group_label>Accelerated Corneal Cross-linking</arm_group_label>
    <arm_group_label>Sham Accelerated Corneal Cross-linking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with infectious keratitis (initial or refractory to treatment) including
             bacterial or mycotic keratitis with size larger than 3 mm

        Exclusion Criteria:

          -  herpetic keratitis

          -  Acanthamoeba keratitis

          -  pregnancy

          -  endophthalmitis

          -  systemic immunosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Graue-Hernandez, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Oftalmologia Fundacion Conde de Valenciana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucero Pedro-Aguilar, MD</last_name>
    <phone>+5255880000</phone>
    <phone_ext>3204</phone_ext>
    <email>lu.pedroaguilar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aida Jimenez-Corona, PhD</last_name>
    <phone>+5255880000</phone>
    <phone_ext>3123</phone_ext>
    <email>aidaajc@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Oftalmologia Conde de Valenciana</name>
      <address>
        <city>Mexico City</city>
        <zip>06800</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucero Pedro-aguilar, MD</last_name>
      <email>lu.pedroaguilar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Enrique Graue-Hernandez, MD, MSc</last_name>
      <email>egraueh@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Li Z, Jhanji V, Tao X, Yu H, Chen W, Mu G. Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol. 2013 May;97(5):669-71. doi: 10.1136/bjophthalmol-2012-302518. Epub 2013 Jan 26.</citation>
    <PMID>23355529</PMID>
  </results_reference>
  <results_reference>
    <citation>Morén H, Malmsjö M, Mortensen J, Ohrström A. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea. 2010 Jan;29(1):102-4. doi: 10.1097/ICO.0b013e31819c4e43.</citation>
    <PMID>19730094</PMID>
  </results_reference>
  <results_reference>
    <citation>Anwar HM, El-Danasoury AM, Hashem AN. Corneal collagen crosslinking in the treatment of infectious keratitis. Clin Ophthalmol. 2011;5:1277-80. doi: 10.2147/OPTH.S24532. Epub 2011 Sep 7.</citation>
    <PMID>21966201</PMID>
  </results_reference>
  <results_reference>
    <citation>Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW Jr. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012 Oct;28(10):706-13. doi: 10.3928/1081597X-20120921-06.</citation>
    <PMID>23062001</PMID>
  </results_reference>
  <results_reference>
    <citation>Alio JL, Abbouda A, Valle DD, Del Castillo JM, Fernandez JA. Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. J Ophthalmic Inflamm Infect. 2013 May 29;3(1):47. doi: 10.1186/1869-5760-3-47.</citation>
    <PMID>23718849</PMID>
  </results_reference>
  <results_reference>
    <citation>Uddaraju M, Mascarenhas J, Das MR, Radhakrishnan N, Keenan JD, Prajna L, Prajna VN. Corneal Cross-linking as an Adjuvant Therapy in the Management of Recalcitrant Deep Stromal Fungal Keratitis: A Randomized Trial. Am J Ophthalmol. 2015 Jul;160(1):131-4.e5. doi: 10.1016/j.ajo.2015.03.024. Epub 2015 Apr 1.</citation>
    <PMID>25841317</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectious keratitis</keyword>
  <keyword>Cross-linking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators describe demographic characteristics of the participants, such as age, gender, etiology, intervention group and the response variables, complications and corneal healing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

